Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 5:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Metformin HCL Clear all
Completed Phase 2 Interventional Results available

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

NCT01011868
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773 placebo, BI 10773 low dose, BI 10773 high dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Sep 28, 2026, 5:06 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

NCT07372625
View directory record Official record
Conditions
TP53 Y220C Mutation, Advanced Solid Tumors
Interventions
metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet, midazolam hydrochloride syrup, rezatapopt
Drug
Lead sponsor
PMV Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Denver, Colorado • Orlando, Florida • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 3 Interventional Results available

Adjunctive Metformin Therapy in Double Diabetes

NCT01334125
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
10 Years to 20 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 1 Interventional Results available

A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients

NCT01298518
View directory record Official record
Conditions
Type 2 Diabetes Patients
Interventions
PF-04620110, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
3
States / cities
Chula Vista, California • DeLand, Florida • Miami Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Nov 5, 2012 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 3 Interventional Results available

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

NCT01618162
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
44
States / cities
Anaheim, California • Garden Grove, California • La Jolla, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics

NCT00240370
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Muraglitazar
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
70
States / cities
Birmingham, Alabama • Columbiana, Alabama • Mesa, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults

NCT07066722
View directory record Official record
Conditions
HIV Infections
Interventions
VH4524184, Itraconazole, Rifabutin, Phenytoin, Metformin, Digoxin
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 60 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 2 Interventional

A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin

NCT00266253
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
GK Activator (2), Metformin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
30 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Phoenix, Arizona • Chula Vista, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

NCT01646320
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo matching with Dapagliflozin, Saxagliptin, Metformin immediate release (IR)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
26
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Sep 28, 2026, 5:06 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

PGC-1 & Muscle Mitochondrial Dysfunction in Diabetes

NCT02282423
View directory record Official record
Conditions
Diabetes, Obesity
Interventions
Pre-study dietary and exercise instruction., Screening examination and oral glucose tolerance test, Euglycemic clamp, VO2max., Acute exercise bout, Percutaneous needle muscle biopsies
Behavioral · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 59 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 2 Interventional Results available

Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer

NCT03800602
View directory record Official record
Conditions
Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer, Stage IVC Colorectal Cancer, Colorectal Cancer Metastatic
Interventions
Metformin, Nivolumab
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Sep 28, 2026, 5:06 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Sugar Challenge Study

NCT04621656
View directory record Official record
Conditions
Type 2 Diabetes, Pre-Diabetes, Healthy
Interventions
January Mobile Application (Sugar AI)
Combination Product
Lead sponsor
January, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,022 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2020 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 2 Interventional Results available

A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY

NCT04617275
View directory record Official record
Conditions
Diabetes, Obesity
Interventions
PF-06882961, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
38
States / cities
Phoenix, Arizona • Searcy, Arkansas • Montclair, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

NCT00712673
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered

NCT01068743
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
saxagliptin, metformin, saxagliptin + metformin (FDC tablet)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of CIN-107 on the Pharmacokinetics of the MATE Substrate, Metformin, in Healthy Subjects

NCT05526690
View directory record Official record
Conditions
Hypertension
Interventions
Metformin, CIN-107
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 28, 2026, 5:06 PM EDT
Terminated Phase 2Phase 3 Interventional

Mechanisms of Improved Wound Healing and Protein Synthesis of Insulin and Metformin

NCT01666665
View directory record Official record
Conditions
Insulin Resistance, Hypermetabolism, Hyperglycemia
Interventions
Metformin, Sugar pill
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
10 Years to 19 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 3 Interventional

A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes

NCT00909597
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
pioglitazone, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
57
States / cities
Buena Park, California • Chino, California • Los Angeles, California + 52 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 4 Interventional

Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin

NCT00384215
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
insulin glargine [rDNA origin] injection
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 79 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

NCT01541215
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
10 Years to 17 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 4 Interventional

Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy

NCT00358124
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
insulin glargine, rosiglitazone, metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Sep 28, 2026, 5:06 PM EDT
Not yet recruiting Early Phase 1 Interventional

Metformin and ACLR Muscle Recovery

NCT07699367
View directory record Official record
Conditions
Atrophy, Inflammation, Weakness, Muscle
Interventions
Metformin, Placebo
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics

NCT00951899
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Colesevelam, Placebo, Diet, Metformin
Drug · Other · Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 10, 2013 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 4 Interventional Results available

A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin

NCT00386100
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Avandamet 6 mg/1500 mg (ttd), Avandamet 4 mg/1000 mg (ttd), Avandamet 2 mg/500 mg (ttd), Avandamet 8 mg/ 2000 mg (ttd), Metformin 500 mg (ttd), Metformin 1000 mg (ttd), Metformin 1500 mg (ttd), Metformin 2000 mg (ttd)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
71
States / cities
Tuscaloosa, Alabama • Gilbert, Arizona • Glendale, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Sep 28, 2026, 5:06 PM EDT